FDA fast-tracks review of three psychedelic drugs after Trump order
Get the Well Enough newsletter with Harry Bullmore for tips on living a healthier, happier and longer life Get the Well Enough email with Harry Bullmore Get the Well Enough email with Harry Bullmore The FDA has announced an “ultra-fast” review of three psychedelic drugs aimed at treating mental health conditions including depression, signaling a significant commitment from the Trump administration to this experimental therapeutic approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to accelerate access and ease restrictions on psychedelics, a class of hallucinogenic drugs that remain illegal under federal law. The FDA confirmed it has awarded priority review vouchers to two companies researching psilocybin – the active ingredient in magic mushrooms – for difficult-to-treat forms of depression. A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not disclose the names of these companies in its press release. While these vouchers do not guarantee approval, they indicate that regulators will aim to shorten their …


